Protein in prostate biopsies signals increased cancer risk
Their findings, reported in the Journal of Clinical Oncology, are the first to quantify, in the setting of a clinical trial, the increased risk of prostate cancer development from the protein ERG. Traditional means of determining risk of prostate cancer — blood tests for the protein prostate-specific antigen (PSA) and biopsies — do not always correlate well with the chances of dying from the disease. Decisions on what to do with the results of these tests can be unclear, leaving doctors and patients frustrated and unsure of how to proceed. …